Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

The review discussed the cutaneous adverse events associated with Epidermal Growth Factor Receptor (EGFR) inhibitors, commonly used in cancer treatment, such as acneiform rash, xerosis, pruritus, and paronychia. It emphasized the importance of early recognition and management of these skin toxicities to improve patient quality of life and adherence to therapy. Prophylactic use of antibiotics like tetracycline and doxycycline significantly reduced the severity of skin rashes and folliculitis, though they did not lower the incidence. Other treatments like tazarotene, pimecrolimus, and high SPF sunscreen showed mixed results. The review highlighted the need for optimized management strategies to allow patients to continue benefiting from EGFRI therapy.